Clinical trials: Arterial Obstructive Diseases
Acute Coronary Syndrome
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome
The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS)…
- Trial name
- V-INCEPTION (NCT04873934)
- Testing
- Inclisiran
- Where
- 88 sites in United States
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
Primary Objective: To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and…
- Trial name
- NCT01663402
- Testing
- Alirocumab, LMT
- Where
- 1,388 sites in United States, Argentina and 55 more
- Volunteers
- 18,924 people
- Sponsor
- Sanofi
Cardiovascular Diseases, Coronary Disease
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
The purpose of the ISCHEMIA trial is to determine the best management strategy for higher-risk patients with stable ischemic heart disease (SIHD).
- Conditions
- Cardiovascular Diseases, Coronary Disease, Coronary Artery Disease, Heart Diseases
- Trial name
- ISCHEMIA (NCT01471522)
- Testing
- cardiac catheterization, coronary artery bypass graft surgery, percutaneous coronary intervention
- Where
- 320 sites in United States, Argentina and 35 more
- Volunteers
- 5,179 people
- Sponsor
- NYU Langone Health
Peripheral Arterial Disease
Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease
This investigation will be conducted in subjects >18 years of age with PAD. Platelet activation and aggregation, and biomarkers associated with platelet activation, oxidative stress, and inflammation will be assessed prior to…
- Trial name
- NCT03247972
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Inova Health Care Services
Coronary Artery Disease, Stable Angina
Comparative Effectiveness of Decision Aids for Stable Chest Discomfort
The purpose of the study is to compare two different types of decision support materials for patients considering treatment for chest pain or chest discomfort from heart disease.
- Trial name
- NCT02652208
- Testing
- Online decision aid, Video decision aid
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Coronary Artery Disease
Hemostasis With QuikClot® Radial® Pad Versus TR Band® After Transradial Artery Access
To evaluate the efficacy and safety of the QuikClot® Radial® pad on hemostasis after transradial access (TRA), compared to the standard of care TR Band®, to hopefully develop a safe and efficacious technique to achieve more rapid…
- Trial name
- NCT03535597
- Testing
- Quikclot Radial (QC) Pad
- Where
- United States
- Volunteers
- 355 people
- Sponsor
- Memorial Healthcare System
Peripheral Artery Disease
Radial accEss for nAvigation to Your CHosen Lesion for Peripheral Vascular Intervention: REACH PVI
The objective of this study is to evaluate acute clinical results of orbital atherectomy (OA) via radial artery access, including complication rates and cost effectiveness.
- Trial name
- REACH PVI (NCT03943160)
- Testing
- Diamondback 360 Extended Length Orbital Atherectomy System
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Abbott Medical Devices
Peripheral Arterial Disease
Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++)
This is a multi-center, non-randomized, single arm study of the SilverHawk™ /TurboHawk™ plaque excision systems when used in conjunction with SpiderFX™ embolic protection device in treatment of moderate to severely calcified…
- Trial name
- NCT00733135
- Testing
- SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device
- Volunteers
- 133 people
- Sponsor
- Medtronic Endovascular
Pulmonary Artery Stenosis
Cutting Balloon Study
The primary objective of this study is to evaluate the safety and efficacy of transcatheter Cutting Balloon therapy for branch pulmonary artery stenosis resistant to low pressure dilation.
- Trial name
- CB (NCT01205568)
- Testing
- Transcatheter Cutting Balloon therapy, High Pressure Balloon Angioplasty
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Boston Children's Hospital
Coronary Artery Disease
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)
XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Trial name
- XVU-Phase 1 (NCT00676520)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- United States
- Volunteers
- 8,053 people
- Sponsor
- Abbott Medical Devices
Type 2 Diabetes, Peripheral Arterial Disease
Liraglutide and Peripheral Artery Disease
STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of cardio-metabolic risk factors, in people with…
- Trial name
- STARDUST (NCT04881110)
- Testing
- Liraglutide, Control
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
Carotid Artery Stenosis, Cerebral Infarction
Bacteria in Atherosclerotic Plaques and Adverse Events
This study is a prospective, multicenter cohort study conducted in western China. The registry study is primarily conducted at the Department of Neurosurgery, Tangdu Hospital, with participation from the Departments of…
- Conditions
- Carotid Artery Stenosis, Cerebral Infarction, Diabetes, Bacteria
- Trial name
- NCT06935279
- Testing
- Carotid Endarterectomy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tang-Du Hospital
Heart Disease, Ischemic, Atherosclerosis, Coronary
Comprehensive Evaluation of Ischemic Heart Disease Using MRI
The purpose of the study is to assess the diagnostic performance of fully automated motion corrected (MC) first pass myocardial perfusion MRI, compared to the original non-corrected first pass myocardial perfusion images in a…
- Trial name
- NCT01234870
- Testing
- Gadolinium, Adenosine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Coronary Artery Disease
Coronary Artery Revascularization in Diabetes
This is a randomized, multi-site, clinical trial comparing percutaneous coronary stenting (PCI) with drug eluding stents to coronary bypass for angiographically significant coronary artery disease in diabetes.
- Trial name
- VA CARDS (NCT00326196)
- Testing
- Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)
- Where
- 26 sites in United States
- Volunteers
- 198 people
- Sponsor
- US Department of Veterans Affairs
Coronary Artery Disease
PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM PK (NCT01510327)
- Testing
- PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
- Where
- 5 sites in United States, Japan
- Volunteers
- 22 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease
This is a Phase 2a randomized, double-blind (subject/investigator blinded, MedImmune unblinded), placebo-controlled, dose-escalation study to evaluate the safety, PK/PD, and immunogenicity of single IV and SC MEDI6012 doses in…
- Trial name
- NCT02601560
- Testing
- MEDI6012
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- MedImmune LLC
Vitamin D Deficiency, Coronary Artery Disease
Vitamin D Repletion in Coronary Artery Disease
Vitamin D (Vit D) status is an emerging risk marker of great interest in cardiovascular disease (CVD). Lower serum levels of Vit D are associated with both cardiac risk factors and prevalent cardiovascular disease.
- Conditions
- Vitamin D Deficiency, Coronary Artery Disease, Endothelial Dysfunction, Inflammation
- Trial name
- NCT01570309
- Testing
- Ergocalciferol, Sugar pill
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Seth I. Sokol, M.D.
Atherosclerosis, Stroke
Carotid Revascularization Endarterectomy Versus Stenting Trial
The purpose of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is to compare the relatively new procedure of stent-assisted carotid angioplasty (CAS) to the traditional and accepted surgical approach of…
- Conditions
- Atherosclerosis, Stroke, Carotid Stenosis, Cerebral Infarction
- Trial name
- CREST (NCT00004732)
- Testing
- Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS)
- Where
- 115 sites in United States, Canada
- Volunteers
- 2,502 people
- Sponsor
- Rutgers, The State University of New Jersey
Coronary Artery Disease
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
Polymorphisms of the cytochrome P450 (CYP) 2C19 enzyme has been consistently shown to modulate clopidogrel response. Accordingly, the Food and Drug Administration (FDA) has issued a warning on the potential for reduced efficacy…
- Trial name
- NCT03489863
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Florida
Coronary Artery Disease
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM LL (NCT01500434)
- Testing
- PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
- Where
- 30 sites in United States, Australia and 5 more
- Volunteers
- 102 people
- Sponsor
- Boston Scientific Corporation